文献速递呼吸危重症与机械通气

接受VV ECMO患者的输血实践:PROTECMO前瞻性多中心观察研究

Transfusion practice in patients receiving VV ECMO (PROTECMO): a prospective, multicentre, observational study.
PubMed 文献 · Lancet Respir Med · 2022-10-11

PROTECMO是一项在41个ECMO中心开展的前瞻性队列研究,纳入604例接受VV ECMO的ARDS患者,旨在描述血红蛋白监测值、输血率及输血阈值。仅当血红蛋白低于7 g/dL时输血与ICU死亡风险降低相关。

核心结论

  • VV ECMO期间无普遍接受的输血阈值,但仅当血红蛋白低于7 g/dL时输血与较低死亡率一致相关。

研究设计与样本

  • PROTECMO为前瞻性多中心队列研究,在41个ECMO中心开展。
  • 纳入604例接受VV ECMO的成人ARDS患者,排除年龄小于18岁、无法知情同意及ECMO停留不足24小时者。
  • 主要监测每日血红蛋白浓度、输血时血红蛋白值及输血率,采用边际结构模型进行校正估计。

主要发现

  • 2432个ECMO日(31%)进行了红细胞输注,504例(83%)患者至少接受1单位红细胞。

临床怎么用

  • VV ECMO期间可考虑限制性输血策略,但需注意血红蛋白低于7 g/dL与死亡风险升高相关。
  • 输血决策应结合临床理由,不应仅依据血红蛋白数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients receiving venovenous (VV) extracorporeal membrane oxygenation (ECMO) packed red blood cell (PRBC) transfusion thresholds are usually higher than in other patients who are critically ill. Available guidelines suggest a restrictive approach, but do not provide specific recommendations on the topic. The main aim of this study was, in a short timeframe, to describe the actual values of haemoglobin and the rate and the thresholds for transfusion of PRBC during VV ECMO. METHODS: PROTECMO was a multicentre, prospective, cohort study done in 41 ECMO centres in Europe, North America, Asia, and Australia. Consecutive adult patients with acute respiratory distress syndrome (ARDS) who were receiving VV ECMO were eligible for inclusion. Patients younger than 18 years, those who were not able to provide informed consent when required, and patients with an ECMO stay of less than 24 h were excluded. Our main aim was to monitor the daily haemoglobin concentration and the value at the point of PRBC transfusion, as well as the rate of transfusions. The practice in different centres was stratified by continent location and case volume per year. Adjusted estimates were calculated using marginal structural models with inverse probability weighting, accounting for baseline and time varying confounding. FINDINGS: Between Dec 1, 2018, and Feb 22, 2021, 604 patients were enrolled (431 [71%] men, 173 [29%] women; mean age 50 years [SD 13·6]; and mean haemoglobin concentration at cannulation 10·9 g/dL [2·4]). Over 7944 ECMO days, mean haemoglobin concentration was 9·1 g/dL (1·2), with lower concentrations in North America and high-volume centres. PRBC were transfused on 2432 (31%) of days on ECMO, and 504 (83%) patients received at least one PRBC unit. Overall, mean pretransfusion haemoglobin concentration was 8·1 g/dL (1·1), but varied according to the clinical rationale for transfusion. In a time-dependent Cox model, haemoglobin concentration of less than 7 g/dL was consistently associated with higher risk of death in the intensive care unit compared with other higher haemoglobin concentrations (hazard ratio [HR] 2·99 [95% CI 1·95-4·60]); PRBC transfusion was associated with lower risk of death only when transfused when haemoglobin concentration was less than 7 g/dL (HR 0·15 [0·03-0·74]), although no significant effect in reducing mortality was reported for transfusions for other haemoglobin classes (7·0-7·9 g/dL, 8·0-9·9 g/dL, or higher than 10 g/dL). INTERPRETATION: During VV ECMO, there was no universally accepted threshold for transfusion, but PRBC transfusion was invariably associated with lower mortality only when done with haemoglobin concentration of less than 7 g/dL. FUNDING: Extracorporeal Life Support Organization.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Martucci G, Schmidt M, Agerstrand C, et al. Transfusion practice in patients receiving VV ECMO (PROTECMO): a prospective, multicentre, observational study. Lancet Respir Med. 2022. PMID: 36240836. doi:10.1016/S2213-2600(22)00353-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。